- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes $1.55M (U.S.) note financing | 1 | Stockwatch | ||
| 18.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting | 1.020 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual... ► Artikel lesen | |
| 11.04. | Sharp Therapeutics Corp (2): Sharp seeks replacement compound for Gaucher, GBA1 | 1 | Stockwatch | ||
| 11.04. | Sharp Therapeutics Corp (2): Sharp closes $200k (U.S.) fourth tranche of placement | 3 | Stockwatch | ||
| SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs | 911 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term... ► Artikel lesen | |
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering | 957 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 03.04. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes third tranche of offering | 1 | Stockwatch | ||
| 02.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering | 837 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| 14.03. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes second tranche of placement | 2 | Stockwatch | ||
| 13.03. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering | 833 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 28.02. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes first tranche of financing | 3 | Stockwatch | ||
| 27.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering | 527 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that... ► Artikel lesen | |
| 03.02. | Sharp Therapeutics Corp (2): Sharp arranges $3-million (U.S.) note offering | 1 | Stockwatch | ||
| 02.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes | 342 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms... ► Artikel lesen | |
| 27.01. | Sharp Therapeutics Corp (2): Sharp Therapeutics appoints Ely to advisory board | 2 | Stockwatch | ||
| 27.01. | Gaucher disease expert Robin Ely joins Sharp Therapeutics advisory board | 2 | Investing.com | ||
| 19.12.25 | Sharp Therapeutics announces $10M non-brokered private placement | 2 | Seeking Alpha | ||
| 19.12.25 | Sharp Therapeutics Corp.: Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options | 610 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that... ► Artikel lesen | |
| 26.11.25 | Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update | 387 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed... ► Artikel lesen | |
| 14.10.25 | Sharp Therapeutics Corp.: Sharp Therapeutics Arranges Non-Brokered Private Placement | 404 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RELAY THERAPEUTICS | 12,070 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported... ► Artikel lesen | |
| NUVALENT | 101,00 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,27 | 0,00 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| ERASCA | 10,320 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,330 | 0,00 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| DYNE THERAPEUTICS | 15,920 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | - Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,300 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 19,500 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,850 | 0,00 % | Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now | ||
| PRAXIS PRECISION MEDICINES | 321,05 | +0,14 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 26,030 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) | ||
| COGENT BIOSCIENCES | 31,260 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| ABSCI | 4,630 | 0,00 % | Speicher und Bürgerenergie prägen ABSI-Jahrestagung in Neuötting | Auf der 33. Jahrestagung der Arbeitsgemeinschaft Bayerischer Solarinitiativen (ABSI) diskutierten rund 240 Fachleute über die zukünftige Rolle von Stromspeichern und Bürgerenergie. Im Zentrum stand... ► Artikel lesen | |
| TYRA BIOSCIENCES | 33,750 | -0,09 % | Wolfe Research initiates Tyra Biosciences stock at Peerperform | ||
| SUMMIT THERAPEUTICS | 15,860 | +0,06 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) |
SHARP THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHARP THERAPEUTICS CORP finden Sie auf Wallstreet Online.